-
公开(公告)号:US20100104567A1
公开(公告)日:2010-04-29
申请号:US12529425
申请日:2008-03-05
IPC分类号: A61K39/395 , A61K31/5377 , A61K31/416 , A61K31/4439 , A61K31/496 , A61K31/454 , A61K38/16 , A61K31/7064 , A61K31/704 , A61K31/4353 , A61K31/437 , A61K31/69 , A61P35/00
CPC分类号: A61K45/06 , A61K31/136 , A61K31/198 , A61K31/416 , A61K31/436 , A61K31/4439 , A61K31/454 , A61K31/4745 , A61K31/475 , A61K31/496 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/69 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K16/3084 , A61K2300/00
摘要: The present invention provides a pharmaceutical composition comprising a combination of an Flt-3 inhibitor and at least one compound, the said pharmaceutical composition wherein an Flt-3 inhibitor is an indazole derivative represented by Formula (I) (wherein R1 represents substituted or unsubstituted aryl, or the like) or a pharmaceutically acceptable salt thereof, the said pharmaceutical composition wherein an Flt-3 inhibitor is a pyrimidine derivative represented by Formula (II) [wherein —X—Y—Z— represents —O—CR17═N— (wherein R17 represents a hydrogen atom, lower alkyl, or the like), R15 represents —NR22aR22b (wherein R22a and R22b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), and R16 represents —NR24aR24b (wherein R24a and R24b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), or the like] or a pharmaceutically acceptable salt thereof, or the like.
摘要翻译: 本发明提供包含Flt-3抑制剂和至少一种化合物的组合的药物组合物,所述药物组合物,其中Flt-3抑制剂是由式(I)表示的吲唑衍生物(其中R 1表示取代或未取代的芳基 或其药学上可接受的盐,其中Flt-3抑制剂是由式(II)表示的嘧啶衍生物[其中-X-Y-Z-表示-O-CR 17 = N-( 其中R17表示氢原子,低级烷基等),R15表示-NR22aR22b(其中R22a和R22b可以相同或不同,各自表示氢原子,取代或未取代的低级烷基等),R16 表示-NR24aR24b(其中R24a和R24b可以相同或不同,各自表示氢原子,取代或未取代的低级烷基等)或药学上可接受的 其盐等。